Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Rodent models of streptozotocin-induced diabetic nephropathy.

Tesch GH, Allen TJ.

Nephrology (Carlton). 2007 Jun;12(3):261-6. Review.

PMID:
17498121
2.

Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease.

Menini S, Iacobini C, Oddi G, Ricci C, Simonelli P, Fallucca S, Grattarola M, Pugliese F, Pesce C, Pugliese G.

Diabetologia. 2007 Dec;50(12):2591-9. Epub 2007 Sep 28.

PMID:
17901943
3.

A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes.

Gong D, Lu J, Chen X, Reddy S, Crossman DJ, Glyn-Jones S, Choong YS, Kennedy J, Barry B, Zhang S, Chan YK, Ruggiero K, Phillips AR, Cooper GJ.

Diabetologia. 2008 Sep;51(9):1741-51. doi: 10.1007/s00125-008-1088-7. Epub 2008 Jul 18.

PMID:
18636238
4.

Effect of cicaprost on the progression of diabetic nephropathy in uninephrectomized streptozotocin-induced diabetic rats.

Robles RG, Villa E, Rábano A, Alvarez E, Martínez J, Ruilope LM, Sancho JM.

J Hypertens Suppl. 1993 Dec;11(5):S208-9. No abstract available.

PMID:
8158348
5.

Generation of insulin-secreting cells from pancreatic acinar cells of animal models of type 1 diabetes.

Okuno M, Minami K, Okumachi A, Miyawaki K, Yokoi N, Toyokuni S, Seino S.

Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E158-65. Epub 2006 Aug 22.

6.

[The morphology of diabetic nephropathy in experimental diabetes induced by low doses of streptozotocin].

Varshavskiĭ VA, Ponomarev AB, Bazarova AV, Karelin AA, Pankov IuA, Kondrat'ev IaIu, Keda IuM, Gorskova VA.

Arkh Patol. 1990;52(7):43-8. Russian.

PMID:
2149496
7.

Use of genetic mouse models in the study of diabetic nephropathy.

Allen TJ, Cooper ME, Lan HY.

Curr Atheroscler Rep. 2004 May;6(3):197-202. Review.

PMID:
15068744
8.

Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure.

Pfab T, Thöne-Reineke C, Theilig F, Lange I, Witt H, Maser-Gluth C, Bader M, Stasch JP, Ruiz P, Bachmann S, Yanagisawa M, Hocher B.

J Am Soc Nephrol. 2006 Apr;17(4):1082-9. Epub 2006 Feb 22.

9.

A model for diabetic nephropathy: advantages of the inducible cAMP early repressor transgenic mouse over the streptozotocin-induced diabetic mouse.

Inada A, Kanamori H, Arai H, Akashi T, Araki M, Weir GC, Fukatsu A.

J Cell Physiol. 2008 May;215(2):383-91. doi: 10.1002/jcp.21316.

PMID:
18270980
10.

Endothelial nitric oxide synthase.

Nakagawa T, Johnson RJ.

Contrib Nephrol. 2011;170:93-101. doi: 10.1159/000324954. Epub 2011 Jun 9. Review.

PMID:
21659762
11.

Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats.

Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y.

J Endocrinol. 2009 Jan;200(1):53-61. doi: 10.1677/JOE-08-0424. Epub 2008 Oct 17.

12.

Use of genetic mouse models in the study of diabetic nephropathy.

Allen TJ, Cooper ME, Lan HY.

Curr Diab Rep. 2004 Dec;4(6):435-40. Review.

PMID:
15539008
13.

Apoptosis induced by endoplasmic reticulum stress involved in diabetic kidney disease.

Liu G, Sun Y, Li Z, Song T, Wang H, Zhang Y, Ge Z.

Biochem Biophys Res Commun. 2008 Jun 13;370(4):651-6. doi: 10.1016/j.bbrc.2008.04.031. Epub 2008 Apr 15.

PMID:
18420027
14.

Functional abnormalities in isolated arteries from Goto-Kakizaki and streptozotocin-treated diabetic rat models.

Brøndum E, Nilsson H, Aalkjaer C.

Horm Metab Res. 2005 Apr;37 Suppl 1:56-60. Review.

PMID:
15918112
15.

Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.

Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, Kikuchi T, Lapointe N, Pojoga L, Williams GH, Ricchiuti V, Adler GK.

Endocrinology. 2006 Nov;147(11):5363-73. Epub 2006 Aug 10.

PMID:
16901964
16.

The effect of streptozotocin and streptozotocin-induced diabetes on the kidney.

Evan AP, Mong SA, Gattone VH, Connors BA, Aronoff GR, Luft FC.

Ren Physiol. 1984;7(2):78-89.

PMID:
6231704
17.

Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.

Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S, Kobara M, Nakata T.

Eur J Pharmacol. 2008 Jul 28;589(1-3):264-71. doi: 10.1016/j.ejphar.2008.06.019. Epub 2008 Jun 10.

PMID:
18582458
18.

Galactosemic nephropathy in the rat.

Lorentz WB Jr, Shihabi ZK, Weidner N.

Clin Physiol Biochem. 1987;5(5):261-7.

PMID:
3652601
19.

Hyperglycemia and renin-dependent hypertension synergize to model diabetic nephropathy.

Conway BR, Rennie J, Bailey MA, Dunbar DR, Manning JR, Bellamy CO, Hughes J, Mullins JJ.

J Am Soc Nephrol. 2012 Mar;23(3):405-11. doi: 10.1681/ASN.2011060577. Epub 2011 Dec 22.

Supplemental Content

Support Center